Skip to main content
  • HOST BR Trial Shows 3-Month DAPT Superior to 1-Month in HBR Patients, Noninferior to 12-Months in LBR Patients

    In patients at high bleeding risk (HBR), 3-month dual antiplatelet therapy (DAPT) is superior to 1-month DAPT with similar bleeding risk, and 3-month DAPT is noninferior to 12-month DAPT, and had significantly lower bleeding risk, in patients with low bleeding risk (LBR), a new study shows. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details